Hepatectomy plus adjuvant transcatheter arterial chemoembolization improves the survival rate of patients with multicentric occurrence of hepatocellular carcinoma

Xu,Da; Liu,Xiaofeng; Wang,Lijun; Xing,Baocai

doi:10.3892/ol.2018.9333

Hepatectomy plus adjuvant transcatheter arterial chemoembolization improves the survival rate of patients with multicentric occurrence of hepatocellular carcinoma

Authors:
- Da Xu
- Xiaofeng Liu
- Lijun Wang
- Baocai Xing
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: August 20, 2018 https://doi.org/10.3892/ol.2018.9333
Pages: 5882-5890
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the role of hepatectomy plus adjuvant transcatheter arterial chemoembolization (TACE) in patients with multicentric occurrence (MO) or intrahepatic metastases (IM) of hepatocellular carcinoma (HCC). Patients with multifocal HCC who underwent hepatic resection only (HR) or HR plus adjuvant TACE (HRT) between January 2005 and December 2015 were divided into MO or IM groups. The patient characteristics and outcomes were retrospectively analyzed. A total of 103 patients (59 and 44 in the MO and IM groups, respectively) were included in the analysis. The 1‑, 3‑ and 5‑year overall survival (OS) rates were 92.7, 76.8 and 56.8% for the MO group, and 93.1, 41.6 and 18.5% for the IM group, respectively (OS, P=0.001), and the 1‑, 3‑ and 5‑year disease‑free survival (DFS) rates were 84.1, 44.6 and 40.5% for the MO group and 51.7, 22.5 and 15.0% for the IM group, respectively (DFS, P<0.001). In the subgroup analysis, the overall survival were significantly better in the MO‑HRT group compared with those in the MO‑HR group (P=0.019), which was also observed between the IM‑HRT and IM‑HR groups (P=0.132). Furthermore, the 1‑, 3‑ and 5‑year OS demonstrated non‑significant differences between patients with <3 and ≥3 tumors in the MO‑HR group (P=0.300), but significantly reduced OS for patients with ≥3 tumors in the IM‑HR group compared with that for patients with <3 tumors (P=0.132). In conclusion, surgical resection combined with adjuvant TACE may result in significantly increased survival rates of patients with MO‑HCC. Tumor number should not be an absolute contradiction to hepatectomy in patients with MO‑HCC.

View Figures

View References

1	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS and Li LQ: Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 260:329–340. 2014. View Article : Google Scholar : PubMed/NCBI
4	Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, et al: A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations?: An observational study of the HCC East-West study group. Ann Surg. 257:929–937. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hsu CY, Liu PH, Hsia CY, Lee YH, Nagaria TS, Lee RC, Lin HC and Huo TI: Surgical resection is better than transarterial chemoembolization for patients with hepatocellular carcinoma beyond the milan criteria: A prognostic nomogram study. Ann Surg Oncol. 23:994–1002. 2016. View Article : Google Scholar : PubMed/NCBI
6	European Association For The Study Of The Liver, ; European Organisation For Research And Treatment Of Cancer, . EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
7	Bruix J and Sherman M; American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M and Makuuchi M; HCC Expert Panel of Japan Society of Hepatology, : Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version. Dig Dis. 29:339–364. 2011. View Article : Google Scholar : PubMed/NCBI
9	Feo F and Pascale RM: Multifocal hepatocellular carcinoma: Intrahepatic metastasis or multicentric carcinogenesis? Ann Transl Med. 3(4)2015.PubMed/NCBI
10	Yasui M, Harada A, Nonami T, Takeuchi Y, Taniguchi K, Nakao A and Takagi H: Potentially multicentric hepatocellular carcinoma: Clinicopathologic characteristics and postoperative prognosis. World J Surg. 21:860–865. 1997. View Article : Google Scholar : PubMed/NCBI
11	Shimada M, Hamatsu T, Yamashita Y, Rikimaru T, Taguchi K, Utsunomiya T, Shirabe K and Sugimachi K: Characteristics of multicentric hepatocellular carcinomas: Comparison with intrahepatic metastasis. World J Surg. 25:991–995. 2001. View Article : Google Scholar : PubMed/NCBI
12	Wang J, Li Q, Sun Y, Zheng H, Cui Y, Li H, Zhou H and Hao X: Clinicopathologic features between multicentric occurence and intrahepatic metastasis of multiple hepatocellular carcinomas related to HBV. Surg Oncol. 18:25–30. 2009. View Article : Google Scholar : PubMed/NCBI
13	Li SL, Su M, Peng T, Xiao KY, Shang LM, Xu BH, Su ZX, Ye XP, Peng N, Qin QL, et al: Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 14:217–223. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sun JJ, Wang K, Zhang CZ, Guo WX, Shi J, Cong WM, Wu MC, Lau WY and Cheng SQ: Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 23:1344–1351. 2016. View Article : Google Scholar : PubMed/NCBI
15	Dong ZR, Zhang PF, Wang CH, Zhang C, Cai JB, Shi GM, Ke AW, Sun HC, Qiu SJ, Zhou J and Fan J: Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: A retrospective analysis. Am J Cancer Res. 5:450–457. 2014.PubMed/NCBI
16	Liu C, Sun L, Xu J and Zhao Y: Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma. World J Surg Oncol. 14:1002016. View Article : Google Scholar : PubMed/NCBI
17	Takenaka K, Adachi E, Nishizaki T, Hiroshige K, Ikeda T, Tsuneyoshi M and Sugimachi K: Possible multicentric occurrence of hepatocellular carcinoma: A clinicopathological study. Hepatology. 19:889–894. 1994. View Article : Google Scholar : PubMed/NCBI
18	Liver Cancer Study Group of Japan, . Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 211:277–287. 1990.PubMed/NCBI
19	Matsumoto Y, Fujii H, Matsuda M and Kono H: Multicentric occurrence of hepatocellular carcinoma: Diagnosis and clinical significance. J Hepatobiliary Pancreat Surg. 8:435–440. 2001. View Article : Google Scholar : PubMed/NCBI
20	Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, et al: Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 149:713–724. 2011. View Article : Google Scholar : PubMed/NCBI
21	Oikawa T, Ojima H, Yamasaki S, Takayama T, Hirohashi S and Sakamoto M: Multistep and multicentric development of hepatocellular carcinoma: Histological analysis of 980 resected nodules. J Hepatol. 42:225–229. 2005. View Article : Google Scholar : PubMed/NCBI
22	Ng IO, Guan XY, Poon RT, Fan ST and Lee JM: Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol. 199:345–353. 2003. View Article : Google Scholar : PubMed/NCBI
23	Chan AC, Chan SC, Chok KS, Cheung TT, Chiu DW, Poon RT, Fan ST and Lo CM: Treatment strategy for recurrent hepatocellular carcinoma: Salvage transplantation, repeated resection, or radiofrequency ablation? Liver Transpl. 19:411–419. 2013. View Article : Google Scholar : PubMed/NCBI
24	Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 14:285–290. 2012. View Article : Google Scholar : PubMed/NCBI
25	Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O and Matsuyama Y: Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. J Hepatol. 58:724–729. 2013. View Article : Google Scholar : PubMed/NCBI
26	Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL and Sangro B: Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 32:348–359. 2012.PubMed/NCBI
27	Xue R, Li R, Guo H, Guo L, Su Z, Ni X, Qi L, Zhang T, Li Q, Zhang Z, et al: Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology. 150:998–1008. 2016. View Article : Google Scholar : PubMed/NCBI
28	Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, Zhao X, Zhang H, Liu S, Zhong Y, et al: Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 61:840–849. 2014. View Article : Google Scholar : PubMed/NCBI
29	Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M and Sassa T: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 25:87–92. 1997. View Article : Google Scholar : PubMed/NCBI
30	Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y and Hino O: Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology. 29:1446–1452. 1999. View Article : Google Scholar : PubMed/NCBI
31	Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, Miyamoto A, Kondo M, Arai I, Yamamoto T, et al: Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol. 39:215–221. 2003. View Article : Google Scholar : PubMed/NCBI
32	Kim PT, Jang JH, Atenafu EG, Fischer S, Greig PD, McGilvray ID, Wei AC, Gallinger S and Cleary SP: Outcomes after hepatic resection and subsequent multimodal treatment of recurrence for multifocal hepatocellular carcinoma. Br J Surg. 100:1516–1522. 2013. View Article : Google Scholar : PubMed/NCBI
33	Taura K, Ikai I, Hatano E, Fujii H, Uyama N and Shimahara Y: Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: An analysis of 610 patients over 16 years old. Ann Surg. 244:265–273. 2006. View Article : Google Scholar : PubMed/NCBI
34	Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM and Wong J: Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Ann Surg. 234:63–70. 2001. View Article : Google Scholar : PubMed/NCBI
35	Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 37:429–442. 2003. View Article : Google Scholar : PubMed/NCBI
36	Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet. 359:1734–1739. 2002. View Article : Google Scholar : PubMed/NCBI
37	Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002. View Article : Google Scholar : PubMed/NCBI
38	Cheng X, Sun P, Hu QG, Song ZF, Xiong J and Zheng QC: Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: A systematic review and meta-analyses. J Cancer Res Clin Oncol. 140:1159–1170. 2014. View Article : Google Scholar : PubMed/NCBI
39	Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, Wu MC and Zhou WP: Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: A RCT. J Hepatol. 61:82–88. 2014. View Article : Google Scholar : PubMed/NCBI
40	Nojiri K, Tanaka K, Takeda K, Ueda M, Matsuyama R, Taniguchi K, Kumamoto T, Mori R and Endo I: The efficacy of liver resection for multinodular hepatocellular carcinoma. Anticancer Res. 34:2421–2426. 2014.PubMed/NCBI